Alpha 2.0
Login Register
» Authors » Mahnaz Asgharnejad

Mahnaz Asgharnejad

Explore the profile of Mahnaz Asgharnejad including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 391
Followers 0
Related Specialties
Neurology
Pharmacology
Psychiatry
Top 10 Co-Authors
Lars Bauer
Erwin Surmann
Venkatesha Murthy
Wei Yin
Babak Boroojerdi
Elisabeth Dohin
Arturo Benitez
Dimitrios Arkilo
Paolo Barone
Steven D Targum
Published In
Parkinsonism Relat Disord
Expert Opin Pharmacother
Br J Clin Pharmacol
Transl Psychiatry
Schizophr Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Development and refinement of the Clinical Global Impression of Improvement for Non-seizure Symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome
Scott Andrews J, Shah D, Nacson A, Symonds T, Hughes S, Asgharnejad M, et al.
J Patient Rep Outcomes . 2025 Feb; 9(1):24. PMID: 39982628
Background: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare, severe, childhood-onset developmental and epileptic encephalopathies characterized by treatment-resistant epilepsy and varying intellectual disability levels. Clinical outcome assessments (COAs) describe...
2.
A review of the putative antiseizure and antiepileptogenic mechanisms of action for soticlestat
Kondo S, Murthy V, Asgharnejad M, Benitez A, Nakashima K, Hawkins N, et al.
Epilepsia . 2025 Feb; PMID: 39963730
Soticlestat (TAK-935) is a potent and selective inhibitor of cholesterol 24-hydroxylase (CYP46A1), an enzyme primarily expressed in the brain that catabolizes cholesterol to 24S-hydroxycholesterol (24HC). In the ELEKTRA phase II...
3.
Concentration-QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study
Yin W, Dote N, Fukase H, Imazaki M, Shimizu K, Takeda S, et al.
Br J Clin Pharmacol . 2024 Sep; 91(2):338-352. PMID: 39313221
Aim: This study aimed to examine the cardiac and overall safety and pharmacokinetic (PK) profiles of soticlestat (TAK-935), an oral, first-in-class selective cholesterol 24-hydroxylase inhibitor. Methods: Data came from a...
4.
Use of video-recordings of site-based interviews for quality assurance in a study of subjects with schizophrenia and persistent negative symptoms
Targum S, Ge T, Asgharnejad M, Reksoprodjo P, Singh J, Murthy V
Schizophr Res . 2024 Aug; 272:61-68. PMID: 39190983
Site-independent ratings derived from audio-digital recordings of site-based interviews are often used for quality assurance monitoring to affirm ratings reliability in CNS clinical trials. The present study of subjects with...
5.
Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
Yin W, Mitra P, Copalu V, Marbury T, Rondon J, Lawitz E, et al.
Pharmacol Res Perspect . 2024 Jul; 12(4):e1213. PMID: 38993008
This phase 1, open-label, three-arm study (NCT05098054) compared the pharmacokinetics and safety of soticlestat (TAK-935) in participants with hepatic impairment. Participants aged ≥18 to <75 years had moderate (Child-Pugh B)...
6.
INTERACT: a randomized phase 2 study of the DAAO inhibitor luvadaxistat in adults with schizophrenia
Murthy V, Hanson E, DeMartinis N, Asgharnejad M, Dong C, Evans R, et al.
Schizophr Res . 2024 Jun; 270:249-257. PMID: 38943928
Deficits in N-methyl-d-aspartate receptor (NMDAR) signaling are implicated in the pathogenesis of schizophrenia. Luvadaxistat (TAK-831/NBI-1065844) is an investigational d-amino acid oxidase (DAAO) inhibitor that increases d-serine levels at NMDAR coagonist...
7.
Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies
Yin W, Facius A, Asgharnejad M, Lahu G, Vakilynejad M
Clin Transl Sci . 2024 Mar; 17(3):e13722. PMID: 38445548
Soticlestat (TAK-935) is a first-in-class, selective inhibitor of cholesterol 24-hydroxylase (CH24H) under phase III development for the treatment of the developmental and epileptic encephalopathies (DEEs), Dravet syndrome (DS), and Lennox-Gastaut...
8.
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers
Yin W, Ballard T, Zhu S, Hsiao S, Chen H, Li Y, et al.
Br J Clin Pharmacol . 2023 Sep; 90(2):516-527. PMID: 37771051
Aims: Our aim was to determine the absolute bioavailability, mass balance, metabolism and excretion of soticlestat (TAK-935). Methods: An open-label, two-period, single-site, phase 1 study was conducted in six healthy...
9.
Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults
Yin W, Facius A, Wagner T, Tsai M, Asgharnejad M, Lahu G, et al.
Clin Transl Sci . 2023 May; 16(7):1149-1162. PMID: 37212649
Soticlestat is a first-in-class, selective inhibitor of cholesterol 24-hydroxylase (CH24H), which catabolizes cholesterol to 24S-hydroxycholesterol (24HC) in the brain, in phase III development for Dravet syndrome and Lennox-Gastaut syndrome treatment....
10.
Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)
Demarest S, Jeste S, Agarwal N, Arkilo D, Asgharnejad M, Hsiao S, et al.
Epilepsy Behav . 2023 Apr; 142:109173. PMID: 37011526
Objective: Chromosome 15q duplication (Dup15q) syndrome and cyclin‑dependent kinase-like 5 deficiency disorder (CDD) are rare neurodevelopmental disorders associated with epileptic encephalopathies, with a lack of specifically approved treatment options. ARCADE...